Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-FU exposure monitoring in perioperative FLOT for resectable gastric or gastroesophageal junction cancer
NL-OMON51680Completed
- Sponsor
- Catharina Ziekenhuis
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of fluorouracil in gastric cancer (GC) and esophagogastric junction cancer, sponsored by Catharina Ziekenhuis. Primary endpoints: Population exposure of 5-FU in FLOT and Percentage of patients achieving target 5-FU AUC. Started Mar 2023; status: completed.
02
Drugs
fluorouracil
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on NL-OMON51680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51680.